Hello, everyone, and how are you this morning? The steam is rising over the Pharmalot corporate campus, where another hot day appears to be unfolding. To fortify ourselves, we are brewing another cup of stimulation, no matter the temperature. Of course, we understand if some of you prefer a bottle of water. Meanwhile, here are some tidbits from around your world. Hope your day goes well and stay cool...
BioSante Drug For Female Sex Drive Spurs Deal Talk (Bloomberg News)
CVS To Close Kansas City Facility, Eliminate 74 Jobs (Kansas City Business Journal)
Novartis CEO Says Drugmaker Is Ready For More Deals (Reuters)
A Big Bet On Seattle Genetics (The Motley Fool)
Bayer Looks To Grow Animal Health Business (Dow Jones)
Merck Benefits From Grants For AIDS Research (Bloomberg News)
EDITOR'S NOTE: Please check this post for updates throughout the morning
steaming coffee thx to dleggett on flickr
1 Comment
Since Pharmalot gets a broad sweep, maybe there are one or two patent attorneys out there who can address this issue.
1) Libigel, BioSante\'s drug for female sexual arousal appears identical to Abbott\'s product Androgel.
2) Abbott holds the formulation and use patents on testosterone gels for hypogonadism, both male and female.
3) Androgel\'s patents are good out to 2020.
4) Therefore, BioSante\'s patents would seem to infringe on Abbott\'s.
Any takers? (and I don\'t mean takers of the gel).